Atrium Therapeutics Posts $19.6M Q1 Revenue and Earns $15M BMS Milestone
RNA•Atrium Therapeutics booked $19.6 million in Q1 collaboration revenue, including a $15 million milestone from Bristol Myers Squibb, while reporting $16.7 million in R&D and $20.3 million in G&A expenses. The company held $267.8 million in cash and expects to submit an ATR 1072 IND in H2 2026.
1. Q1 Financial Results
Atrium reported $19.6 million in collaboration revenue for Q1 2026 following its spin-off, with research and development expenses of $16.7 million and general and administrative expenses of $20.3 million for the period.
2. BMS Collaboration Milestone and Agreement
The company earned a $15 million milestone payment by delivering its first cardiology-focused development candidate to Bristol Myers Squibb. Under the collaboration, Atrium is eligible for up to $1.35 billion in R&D milestones, $825 million in commercial milestones and tiered royalties on net sales.
3. Lead Pipeline Progress
ATR 1072 has completed GLP toxicology studies and pre-IND meetings with the FDA and Health Canada, with an IND submission expected in the second half of 2026. IND-enabling studies for ATR 1086 will begin later in 2026, targeting a 2027 IND filing.
4. Cash Position and Runway
As of March 31, 2026, Atrium held $267.8 million in cash and cash equivalents, which the company believes is sufficient to fund planned operations through key clinical proof-of-concept milestones.
